Hematology

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Condition:   Multiple Myeloma
Interventions:   Drug: GSK2857916 frozen;   Drug: GSK2857916 lyophilized;   Other: NEI-VFQ-25 Questionnaire;   Other: OSDI Questionnaire;   Other: EORTC QLQ-C30 Questionnaire;   Other: EORTC QLQ-MY20 Questionnaire
Sponsor:   GlaxoSmithKline
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 16, 2018 / by / in
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Conditions:   Carcinoma, Small Cell;   Lung Cancer;   Small Cell Lung Cancer
Interventions:   Drug: M7824 (Arm A/B);   Drug: Topotecan;   Drug: Temozolomide
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 13, 2018 / by / in
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Conditions:   Anemia;   Renal Insufficiency, Chronic
Intervention:   Drug: Mircera
Sponsor:   Hoffmann-La Roche
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 12, 2018 / by / in
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Condition:   Multiple Myeloma
Intervention:   Biological: JNJ-68284528
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2018 / by / in
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Condition:   Chronic Granulomatous Disease
Intervention:   Drug: Interferon Gamma-1B
Sponsor:   University of Colorado, Denver
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2018 / by / in
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Condition:   Multiple Myeloma
Interventions:   Combination Product: BCMA CART + huCART19;   Combination Product: CART BCMA or CART BCMA + huCART19;   Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19
Sponsors:   University of Pennsylvania;   Novartis
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2018 / by / in